Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme

M. Wirth, C. Tyrrell, K. Delaere, M Sanchez-Chapado, J. Ramon, Michael Wallace, J. Hetherington, F. Pina, C. Heyns, T. Borchers, T. Morris, J. Armstrong

    Research output: Contribution to journalArticle

    22 Citations (Scopus)
    Original languageEnglish
    Pages (from-to)194-200
    JournalProstate Cancer and Prostatic Diseases
    Volume8
    Publication statusPublished - 2005

    Cite this

    Wirth, M., Tyrrell, C., Delaere, K., Sanchez-Chapado, M., Ramon, J., Wallace, M., Hetherington, J., Pina, F., Heyns, C., Borchers, T., Morris, T., & Armstrong, J. (2005). Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme. Prostate Cancer and Prostatic Diseases, 8, 194-200.